Study Links Injectable Contraceptive DMPA Use After Age 31 to Increased Meningioma Risk

A recent study has identified a significant association between the use of depot medroxyprogesterone acetate (DMPA), a commonly used injectable contraceptive, and an increased risk of meningioma in women. The findings indicate that the risk is particularly elevated among women who use DMPA for extended periods or begin using it after the age of 31.

The research highlights that prolonged exposure to DMPA correlates with a higher likelihood of developing meningioma, a typically benign tumor arising from the meninges, which are the protective layers surrounding the brain and spinal cord. Women who initiated DMPA use later in life, specifically after turning 31, were found to be at greater risk compared to those who began earlier. These findings add to ongoing discussions about potential long-term health implications associated with hormonal contraceptives. Further details regarding the study’s methodology and scope have not been disclosed at this time.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

Date: September 3, 2025

Author

Mark Chiang